Skip to content
Gland Pharma logo

Gland Pharma

GLAND NSE
₹3,159.00 +0.10 (0.00%)
P/E
46.12
View as Markdown
MCP
Close 4 Nov 2026 ₹3,159.00 +1,260.40 +66.4% 1Y
Start ₹1,898.60

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.10%
Debt to Equity
0.03
EPS (TTM)
₹68.49
Book Value
₹627.71
Market Cap
—
P/E (TTM)
46.12
P/B
5.03
ROE
10.70%
Dividend Yield
0.63%
EBITDA
₹1,946 Cr
52W High
₹3,174.00
52W Low
₹1,573.60
Day Range
₹3,124.50 – ₹3,174.00
Volume
4,15,000

Peer Comparison

Healthcare › Pharmaceuticals

Gland Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Gland Pharma (this company)
₹3,159.0046.12₹51,731 Cr5.030.63%10.70%15.10%₹6,725 Cr₹1,129 Cr
Median 8 companies₹2,048.6042.47₹1,25,337 Cr4.900.61%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

62 Good

Data confidence 100/100

insider_selling

Category scores

Quality
58
Good
Returns, margins, earnings quality 22% weight
Valuation
67
Strong
Cheap vs sector & own history 24% weight
Growth
52
Average
Sales & profit trajectory 9% weight
Financial Health
85
Strong
Solvency, leverage, coverage 9% weight
Momentum
89
Strong
Trend strength, vol-adjusted 12% weight
Ownership
62
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.1%

Weaknesses

3
  • Stock is trading at 4.86 times its book value
  • Company has a low return on equity of 9.29% over last 3 years.
  • Promoter holding has decreased over last 3 years: -6.09%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBearish342
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
62.98
Neutral
MACD (12,26,9)
43.69
Bullish
SMA (50)
2,960.06
Bullish
SMA (200)
2,295.87
Bullish

As of

Analyst Rating

Based on 15 analysts
BUY73%

11 of 15 analysts rate Buy, 1 Hold, 3 Sell.

As of

BUY
11
73%
HOLD
1
7%
SELL
3
20%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+13.18%
3Y+21.06%
1Y+14.51%
TTM+17.55%

Net profit

Net profit growth by window
5Y+0.59%
3Y+9.56%
1Y+46.92%
TTM+46.43%

Operating cash flow

Operating cash flow growth by window
5Y+11.25%
3Y+41.49%
1Y+12.68%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−12.25 pp
3Y−2.93 pp
1Y+2.75 pp
TTM+2.04 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹2,633 Cr
Mar 2021₹3,463 Cr
Mar 2022₹4,401 Cr
Mar 2023₹3,625 Cr
Mar 2024₹5,665 Cr
Mar 2025₹5,616 Cr
Mar 2026₹6,431 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹773 Cr
Mar 2021₹997 Cr
Mar 2022₹1,212 Cr
Mar 2023₹781 Cr
Mar 2024₹772 Cr
Mar 2025₹699 Cr
Mar 2026₹1,027 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹438 Cr −20.5% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

As of 2026-11-04, Gland Pharma trades at ₹3,159 with a market cap of ₹51,730.9 Cr, a P/E (TTM) of 46.12x, and a near-zero debt-to-equity ratio of 0.03. The stock has rallied roughly 100% from its 52-week low of ₹1,573.6, with TTM profit growth of 49%, though longer-term 5-year profit CAGR stands at just 1%.

Bull Case 8
  • Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.03, providing significant financial flexibility and resilience against interest-rate cycles.
  • TTM profit growth of 49% signals a sharp earnings recovery, suggesting recent operational momentum is accelerating.
  • Compounded sales growth of 21% over 3 years reflects strong and sustained top-line expansion in the injectable pharma segment.
  • The stock has delivered a 1-year return CAGR of 58%, indicating powerful market re-rating and renewed investor confidence.
  • Healthy dividend payout ratio of 39.1% demonstrates management's commitment to returning cash to shareholders even while funding growth.
  • ROCE of 13.74% as of 2026-11-04 indicates reasonable capital efficiency for a capital-intensive injectable manufacturing business.
  • TTM sales growth of 18% shows continued revenue momentum beyond the 3-year compounded trend, suggesting the growth trajectory remains intact.
  • 3-year stock CAGR of 24% indicates the market has rewarded the company's improving fundamentals over a medium-term horizon.
Bear Case 7
  • 5-year compounded profit growth of just 1% highlights that the recent 49% TTM surge follows a prolonged period of earnings stagnation.
  • Return on equity of 9.92% (and a 3-year average of roughly 9%) is modest, indicating the company has not consistently generated strong returns on shareholder capital.
  • Price-to-book ratio of 5.03x means investors are paying a steep premium over net asset value, which could compress if growth slows.
  • Promoter holding has declined by 6.09% over the last three years, which may signal reduced promoter conviction or dilution-related concerns.
  • The stock trades near its 52-week high of ₹3,174, just ₹15 below the peak, leaving it technically stretched and vulnerable to mean-reversion.
  • 5-year stock CAGR of -4% reminds investors that despite the recent rally, longer-term shareholders who bought at or near the IPO-era highs have seen negative returns over a 5-year horizon.
  • Dividend yield of 0.63% is modest in absolute terms, offering limited income cushion for investors paying a 46x earnings multiple.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

12h ago

TL;DR: Gland Pharma secured a new USFDA approval for a injectable product targeting a $214 million US market opportunity, reinforcing its pipeline momentum in the generic injectables space. No headwinds surfaced in the latest news cycle. The trend is steady, with the new approval providing a modest revenue growth lever going forward.

Positives 1
  • USFDA nod for injectable Nov 03

    Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in 40 mg/mL and 80 mg/mL strengths, bioequivalent to Pfizer's Depo-Medrol. The US market for this molecule is estimated at $214 million for the twelve months ending August 2026.

Quarterly Results

₹ Cr
GLAND quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,209
1,373
1,545
1,537
1,402
1,406
1,384
1,425
1,506
1,487
1,695
1,743
1,800
Expenses
915
1,049
1,189
1,179
1,137
1,109
1,024
1,077
1,138
1,173
1,260
1,230
1,311
Operating Profit
294
324
356
359
264
297
360
348
368
314
435
513
489
OPM %
24%
24%
23%
23%
19%
21%
26%
24%
24%
21%
26%
29%
27%
Other Income
38
53
37
42
51
60
58
44
58
84
39
111
61
Interest
5
6
5
10
6
6
23
7
12
8
4
10
4
Depreciation
65
81
105
93
92
94
96
96
101
106
108
109
111
PBT
261
290
283
298
218
257
299
288
313
284
362
506
435
Tax %
26%
33%
32%
35%
34%
36%
32%
35%
31%
35%
28%
28%
27%
Net Profit
194
194
192
192
144
164
205
187
215
184
261
367
317
EPS (₹)
11.79
11.78
11.65
11.68
8.73
9.93
12.42
11.32
13.08
11.15
15.87
22.26
19.21

Profit & Loss

₹ Cr
GLAND profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,633
3,463
4,401
3,625
5,665
5,616
6,431
6,725
Expenses
1,678
2,161
2,890
2,600
4,332
4,348
4,801
4,974
Operating Profit
955
1,302
1,510
1,025
1,333
1,269
1,630
1,751
OPM %
36%
38%
34%
28%
24%
23%
25%
26%
Other Income
139
135
224
184
170
214
292
296
Interest
7
3
5
7
26
42
33
26
Depreciation
95
99
110
147
345
378
424
434
PBT
993
1,335
1,619
1,055
1,133
1,063
1,465
1,587
Tax %
22%
25%
25%
26%
32%
34%
30%
—
Net Profit
773
997
1,212
781
772
699
1,027
1,129
EPS (₹)
49.88
60.94
73.75
47.42
46.9
42.4
62.35
68.49
Div. Payout %
0%
0%
0%
0%
43%
42%
32%
—

Balance Sheet

₹ Cr
GLAND balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
16
16
16
16
Reserves
3,631
5,887
7,141
7,942
8,707
9,134
10,341
Borrowings
5
5
5
4
372
314
284
Other Liabilities
435
588
671
814
1,515
1,708
1,807
Total Liabilities
4,086
6,496
7,834
8,778
10,611
11,173
12,449
Fixed Assets
968
954
1,502
1,571
3,947
4,147
4,492
CWIP
188
338
191
177
238
151
342
Investments
0
0
155
0
0
0
0
Other Assets
2,929
5,204
5,986
7,030
6,426
6,875
7,614
Total Assets
4,086
6,496
7,834
8,778
10,611
11,173
12,449

Cash Flow

₹ Cr
GLAND cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
701
605
791
364
997
915
1,031
Investing
−761
−1,520
−999
1,211
−1,749
1,718
188
Financing
−7
1,238
35
15
−799
−433
−417
Net Cash Flow
−67
323
−174
1,590
−1,552
2,199
803
Free Cash Flow
530
377
269
141
599
521
538
CFO/OP
99
70
79
66
98
100
91

Ratios

GLAND financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
71
99
88
100
99
107
Inventory Days
250
312
205
421
278
294
284
Days Payable
82
97
80
127
129
143
136
Cash Conversion Cycle
251
286
225
382
250
250
255
Working Capital Days
161
169
168
242
155
173
145
ROCE %
—
28%
25%
15%
14%
12%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Gland Pharma insights

69 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 45.75%
  • DIIs 33.21%
  • FIIs 10.36%
  • Others 6.03%
  • Public 4.63%
  • Government 0.01%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Gland Pharma

What does Gland Pharma Ltd do?
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United…
Where is Gland Pharma Ltd (GLAND) listed?
Gland Pharma Ltd trades as GLAND on the NSE and under code 543245 on the BSE.
Which sector does Gland Pharma Ltd belong to?
Gland Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Gland Pharma Ltd?
Gland Pharma Ltd trades at a PE ratio of 46.12 as of 4 Nov 2026, on earnings per share of ₹68.49, against a book value of ₹627.71 per share.
What is the 52-week high and low of Gland Pharma Ltd?
Over the last 52 weeks Gland Pharma Ltd has traded between ₹1,573.6 and ₹3,174 as of 4 Nov 2026.
Does Gland Pharma Ltd pay dividends?
Gland Pharma Ltd has a dividend yield of 0.63%.
What is the Return on Equity (ROE) of Gland Pharma Ltd?
Gland Pharma Ltd reported a return on equity of 10.70%. Its debt-to-equity ratio is 0.03.

Company Information

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Website glandpharma.com
CEO Mr. Srinivas Sadu
Employees 4,351
Listed 20 Nov 2020
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GLAND.md for Gland Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month